Background and purpose: Drug-related ototoxicity may exacerbate presbycusis (age-related hearing loss); yet, few data are available on the prevalence of ototoxic medication use by older adults. The purposes of this study were to assess the impact of aging and ototoxicity on hearing loss, the prevalence of ototoxic medication use, and select characteristics associated with ototoxic medication use among older adults.
Introduction
Age-related hearing loss or presbycusis is one of the four leading chronic conditions reported by older adults; 30% of adults aged 65-74 years and approximately half of adults older than 75 years report having hearing loss (National Institute on Deafness and Other Communication Disorders, 2017). Age-related hearing loss has multiple negative effects on an individual's physical, psychosocial, and social status (Karpa et al., 2010) . For example, hearing loss is associated with diminished functional status as measured by activities of daily living (Dalton et al., 2003) , as well as quality-of-life scores in both physical and mental domains (Chia et al., 2007) . Data support that many older adults with hearing loss have depression, low self-esteem, and loneliness because of communication difficulties and social isolation (Gopinath et al., 2009; Wallhagen, Strawbridge, Shema, Kurata, & Kaplan, 2001) . Hearing loss affects not only the individual but also family members who may become frustrated as a result of communication difficulties (Lopez-Torres Hidalgo et al., 2009) .
Age is the most common factor associated with developing hearing loss in the adult population (Bielefeld, Tanaka, Chen, & Henderson, 2010) . However, age and exposure to life experiences that damage the inner ear contribute together to the development of hearing loss (Peterson, 1994) . Older adults are often on multiple medications for concurrent chronic illnesses (Kaufman, Kelly, Rosenberg, Anderson, & Mitchell, 2002) , many of which have been identified as ototoxic. Patients taking these ototoxic medications may experience accelerated hearing loss. Ototoxic drug-related hearing loss has been characterized as a bilateral sensorineural loss affecting the higher frequencies, similar to presbycusis (Rybak & Ramkumar, 2007) . Similar to people with presbycusis, people with ototoxic drug-related hearing loss may take their hearing problem for granted or be unaware when it comes on slowly.
Although some studies have evaluated select medications in specific populations, such as infants or patients in hospitals, there are few data on the prevalence of known ototoxic medication use among older adults in the community. Thus, the purposes of this study were to review the impact of aging and ototoxicity on hearing loss, to investigate the prevalence of ototoxic medication use, and to explore characteristics associated with ototoxic medication use among older adults.
Effects of aging and ototoxicity on hearing
From the cochlea to the brain, several structural and chemical changes accompany advancing age. Older adults can have both conductive and sensorineural hearing loss in addition to cognitive difficulties that affect sound interpretation (Walling & Dickson, 2012) . However, the majority of older adults with hearing loss have agerelated sensorineural loss caused mainly by changes within the cochlea. Age-related sensorineural hearing loss is associated with problems in transducing hydromechanical vibrations to electrical potential in the cochlea and/or in auditory nerve transmission to the brain. This hearing loss usually results from permanent damage in the organ of Corti (Walling & Dickson, 2012) . Vulnerable sites in the cochlea that are affected by aging include the hair cells and the stria vascularis (Pickles, 2008) . Loss of hair cells is initially more common in the basal region of the cochlea among older adults, which leads to highfrequency hearing loss (Weinstein, 2000) . Hair cells cannot be replaced and are susceptible to accumulated damage over time from a combination of aging and toxicity from ototoxic medications and other environmental exposures (Lin et al., 2012) . The stria vascularis provides the blood supply to the organ of Corti and maintains the endocochlear resting potential (Lin et al., 2012) . Damage from age-related changes in the stria vascularis results in loss of the endocochlear resting potential, leading to a less effective cochlear amplifier and elevated hearing thresholds (Lin et al., 2012) . These age-related changes cause a gradual, symmetric hearing loss, predominantly of high frequencies (Yueh, Shapiro, MacLean, & Shekelle, 2003) .
Free radicals (reactive oxygen species) are considered to be important causative factors in age-related hearing loss (Liu & Yan, 2007) . The ability to correct the negative effects of oxidative processes becomes less efficient with age, leading to the damage of key cell components, such as mitochondrial DNA. Over time, oxidative damage accumulates in the cochlea and causes tissue dysfunction (Yamasoba et al., 2013) . In addition to the aging process itself, other factors, such as exposure to noise, chemicals, and drugs, can damage the cochlea and contribute to the decline in hearing experienced by older adults (Huang & Tang, 2010) .
Ototoxicity is cellular degeneration in the inner ear caused by a drug's side effects (Rybak & Ramkumar, 2007) . The most common reported ototoxic drugs in clinical use are aminoglycoside antibiotics, macrolide antibiotics, salicylates, and chemotherapeutic agents such as cisplatin, loop diuretics, antimalarials, nonsteroidal antiinflammatory drugs (NSAIDs), quinine, and acetaminophen (Rybak & Ramkumar, 2007; Tabuchi et al., 2011; Walling & Dickson, 2012) . Aminoglycosides can activate the formation of free radicals, which can damage mitochondria in the cochlea and lead to hair cell death (Kovacic & Somanathan, 2008; Pickles, 2008) . Cisplatin affects the outer hair cells, spiral ganglion cells, and stria vascularis. Loop diuretics mainly target the stria vascularis (Pickles, 2008; Rybak & Ramkumar, 2007) . High dose of salicylates and NSAIDs may reduce cochlear blood flow and damage outer hair cells (Cazals, 2000; Jung, Rhee, Lee, Park, & Choi, 1993) . Quinine induces vasoconstriction and decreases cochlear blood flow (Jung et al., 1993) . Acetaminophen can cause oxidative stress, which causes degeneration and impairment of hair cells (Yorgason, Kalinec, Luxford, Warren, & Kalinec, 2010) . However, although these various processes have been identified, the exact mechanisms by which medications cause ototoxicity are still not clear.
Ototoxic drug-related damage could be a more significant contributor to hearing loss in older adults than in younger groups for two major reasons: first, the high prevalence of ototoxic drug use for comorbid chronic diseases, and second, an increased vulnerability to ototoxic drug effects because of impaired renal function (Howarth & Shone, 2006) . Given this, it is important to explore the prevalence of ototoxic medication use by older adults and its relationship to hearing loss.
Methods

Study design and participants
This secondary analysis of cross-sectional data was conducted using selected variables extracted from the existing data sets from two population-based epidemiological studies: Beaver Dam Eye Study (BDES) and Epidemiology of Hearing Loss Study (EHLS). The cohort was examined in 1993-1995, 1998-2000, and 2003-2005 in Beaver Dam, Wisconsin, when the ages of the participants ranged from 48 to 92 years (Cruickshanks et al., 2010) . This study included data from the baseline EHLS examination (1993) (1994) (1995) and the 10-year follow-up (2003-2005) to assess any changes in the use of ototoxic medications. Participants who completed the survey for medication use were included in this study.
Written informed consent was obtained from all study participants at baseline and follow-up examinations. The Health Sciences Institutional Review Board of the University of Wisconsin approved this study, with a waiver of review from the Human Research Protection Program Committee on Human Research of the University of California, San Francisco, because only deidentified data were used.
Study variables and measures
Medication use among the EHLS participants was obtained from the concurrent BDES on the same cohort. Medication use was obtained from the standardized questionnaire (Klein & Klein, 1999) that was administered by the data collector (Klein, Klein, Lee, Cruickshanks, & Gangnon, 2006) . Participants were asked to bring all prescription and over-the-counter medications that they were regularly taking at least once per week. The examiner recorded the medication from the label of the bottle and checked whether the medication bottle was the correct one for the medicine the participant reported taking. The examiner also asked whether there were other medications being taken that were not brought to the interview. If so, the data collector then phoned the participant at home to have the participant read the name of the medication over the phone. When necessary to verify medication and reason for use, the data collector phoned the participants, their physicians, and/or their pharmacies. In addition, participants were asked whether they had a history of hospitalization with fever requiring intravenous antibiotics and if they had a history of receiving chemotherapy. If yes to the latter, they were asked about the type of chemotherapy received, duration of chemotherapy, and age at first chemotherapy. Medications selected for the current study and defined here as "ototoxic medications" were those that have been identified as ototoxic in the literature reviewed above. These included diuretics, NSAIDs, antibiotics, chemotherapeutic agents, quinine, and acetaminophen. Concomitant ototoxic medication use was defined by the use of more than one of these medications.
Hearing loss was defined as a pure tone average at 500, 1,000, 2,000, and 4,000 Hz greater than 25 decibels hearing level (dB HL) in either ear. Trained data collectors administrated the questionnaire at the baseline and 10-year follow-up examinations for medical history, noise exposure, and socioeconomic status (Cruickshanks et al., 2010) . Medical history included self-reported clinician diagnosis of diabetes and cardiovascular disease (CVD) (stroke, heart attack, or angina). Diabetes was defined as a hemoglobin A1c level greater than or equal to 6.5% at the time of the examination or self-reported clinician diagnosis. Hypertension was defined as systolic blood pressure greater than or equal to 140 mm Hg, diastolic blood pressure greater than or equal to 90 mm Hg, or a self-reported clinician diagnosis of hypertension and current use of antihypertensive medication. Noise exposure was assessed by current (within the past year) noisy job. Smoking status was categorized as nonsmoker, past smoker, or current smoker.
Statistical analysis
Descriptive analyses are presented as mean values with standard deviations (SDs) for continuous variables and as frequencies and percentages for categorical variables.
Comparison analyses used the Chi-square test of association for categorical variables and t tests of differences in mean values for continuous variables. Logistic regression was used to evaluate the factors associated with the use of ototoxic medication. Ototoxic medication use was a dichotomous (No/Yes) variable, and the number of ototoxic medication use was a continuous variable. Multicollinearity was checked among independent variables. Statistical significance was defined as p < .05. All statistical analyses were conducted using SPSS software, version 24 (SPSS, Inc., Chicago, IL).
Results
The descriptive characteristics of the participants are shown in Table 1 . The mean age of the 3,574 participants at baseline was 65.1 years (SD = 10.4), more than 50% were women, 46% had hearing loss, and 50% had hypertension. At 10-year follow-up, the mean age of the 2,280 participants was 71.7 years (SD = 8.7), more than 50% were women, 58% had hearing loss, 48% had progression of hearing thresholds greater than 10 dB HL over 10 years, and 76% had hypertension. The prevalence of hearing loss and chronic diseases, such as hypertension, diabetes, and CVD, increased greatly over 10 years.
Participants taking ototoxic medications were more likely to be older and women and to have hypertension, diabetes, CVD, and cancer at baseline. At 10-year followup, participants taking ototoxic medications were more likely to have hypertension.
Prevalence of ototoxic medication use Overall, 84% of participants were using any ototoxic medications at baseline, and the prevalence of ototoxic medication use increased to 91.1% over 10 years (Table 1) . The most common ototoxic medication taken by older adults was NSAIDs (75.2%), followed by acetaminophen (39.9%) and diuretics (35.6%) at 10-year follow-up ( Table 2 ). The number of participants taking NSAIDs and diuretics had substantially increased over 10 years (58.3% vs. 75.2% and 23% vs. 35.6%, respectively) .
Among ototoxic medication users, half of the participants were taking more than one type of ototoxic medication at baseline, and 60% were concomitant users at 10-year follow-up. The mean number of ototoxic medications used was 1.88 (60.89), and more than 21% of the participants were combined users of three or more ototoxic medications at 10-year follow-up (Figure 1) .
The association between any ototoxic medication use and hearing loss was not statistically significant. However, participants taking a greater number of ototoxic medications demonstrated more hearing loss than those taking less at both baseline and 10-year follow-up (Table 3) (Table 4) .
Further analysis was conducted with a subgroup of participants who reported no use of an ototoxic medication at baseline. Among participants who were not Table 1 . Characteristics of participants at baseline and 10-year follow-up taking any ototoxic medication (n = 560) at baseline, 385 participants completed remained at 10-year follow-up. Of these 385 participants, 312 participants were taking ototoxic medication at 10-year follow-up. Age (OR for 10 years = 1.68, 95%, CI [1.11, 2.54]) and hypertension (OR = 2.95, 95% CI [1.58, 5.52]) were associated with the change of ototoxic medication use over 10 years (Table 5 ).
Discussion
The prevalence of any potentially ototoxic medication use increased from 84% at the baseline to 91% at the 10-year follow-up among older adults in this populationbased study. Nonsteroidal anti-inflammatory drugs were the most commonly used medication (75.2%), followed by acetaminophen (39.9%) and diuretics (35.6%) at 10-year follow-up. This high prevalence may be related to the increased prevalence of chronic diseases with age (Forman, Rimm, & Curhan, 2007) . Chronic diseases such as hypertension, CVD, or diabetes were significantly associated with ototoxic medication use in this study. A study using data from the National Health and Nutrition Examination Survey (NHANES) found that 25% of adults aged 20-69 years used ototoxic medications including NSAIDs (7.3%), antineoplastic drugs (5%), loop diuretics (1.5%), and aminoglycoside antibiotics (0.03%) (Bainbridge, Hoffman, & Cowie, 2008) . This NHANES study also found that the prevalence of ototoxic medication use was greater in the hearing loss group than in the normal hearing group (P = .001).
Additional large population-based studies have focused on the association between hearing loss and analgesic uses such as aspirin, NSAIDs, and acetaminophen (Curhan, Eavey, Shargorodsky, & Curhan, 2010; Curhan, Shargorodsky, Eavey, & Curhan, 2012) . In the Nurses' Health Study II, women aged 31-48 years commonly used NSAIDs (69%), acetaminophen (62%), and aspirin (30%) at least once a week (Curhan et al., 2012) . The Health Professionals Follow-Up Study found that in men aged 40-75 years, the prevalence of NSAIDs, aspirin, and acetaminophen was 4.9%, 26.8%, and 5.6%, respectively (Curhan et al., 2010) . In these two studies, NSAIDs and acetaminophen were significantly associated with the risk of selfreported hearing loss, but findings for aspirin were conflicting. Conflicting results for aspirin were also found in other studies (Chen et al., 2007; Jung et al., 1993; Sha, Qiu, & Schacht, 2006) . Aspirin was included within the NSAID category in the current study and not isolated for analysis. In addition, the Health, Aging and Body Composition Study reported that participants were aged from 73 to 84 years and were taking salicylates (44%), loop Note: IV = intravenous; NSAID = nonsteroidal anti-inflammatory drug. diuretics (9.7%), and quinine (1.2%) (Helzner et al., 2005) . Also, the Framingham Heart Study reported that only a very small percentage (0.4%) of the 2,293 participants aged 57-89 years were taking ototoxic medications (Moscicki, Elkins, Baum, & McNamara, 1985) . However, they did not describe in the article which classes of medications were included in their analyses. We found a much higher prevalence of any ototoxic medication use than in other previous studies. This might be related to the inclusion of a greater number of known ototoxic medications than those included in other studies. In addition, in the current study, the prevalence of use of each individual category of ototoxic medication, whether NSAIDs, diuretics, or antibiotics, was also higher than in other prevalence studies. This might be partially explained by the fact that our study included participants who were older than those studied in the NHANES and many of the other studies and continued to follow participants who had entered nursing homes and assisted living, unlike most other studies. These individuals tend to take more medications. In addition, the assessment of ototoxic medication use in the current study actually involved identifying and confirming the medications used and was not just based on the self-report. More than half of the participants used multiple ototoxic medications, and the association between the number of ototoxic medication used and hearing loss was significant. A previous study documented that the impact of concomitant use of more than one class of aspirin, acetaminophen, or NSAIDs on self-reported hearing loss was additive (Curhan et al., 2010) . This may be partly explained by the fact that different classes of ototoxic medications affect the auditory function through different mechanisms (Curhan et al., 2010) .
Hypertension, diabetes, and CVD are frequently found concurrently as comorbid diseases with cardiovascular complications (Sowers, Epstein, & Frohlich, 2001) , although their correlations were low (r < .20) in this study (data not shown). Therefore, it is difficult to tease out the unique variance explained by each factor on ototoxic medication use. However, certain chronic conditions may add significant risk of hearing loss among ototoxic medication users because these diseases themselves are also risk factors for age-related hearing loss (Frisina, Mapes, Kim, Frisina, & Frisina, 2006; Gates, Cobb, D'Agostino, & Wolf, 1993) .
The strengths of the present study include having good quality data, including audiometric data documenting hearing loss, from a large population-based cohort of community-dwelling older adults. The data collected could address the question of prevalence of ototoxic medication use, a topic on which minimal research exists. Data were collected using standardized protocols and methodologies for measuring medication use. However, our study has limitations. The population is mostly non-Hispanic White from Beaver Dam; thus, the results may not be generalizable to other ethnic groups. There was an association between the number of ototoxic medication use and hearing loss, but the association between any ototoxic medication use and hearing loss was not statistically significant in this study. Because this study was cross-sectional, it is difficult to know whether ototoxic medications preceded the hearing loss or vice versa. A longitudinal analysis could help to clarify the association between the incidence of hearing loss and ototoxicity from medications used by older adults. The short-term ototoxic effect of medications is relatively well documented (Lanvers-Kaminsky, Zehnhoff-Dinnesen, Parfitt, & Ciarimboli, 2017) and is generally known to clinicians. However, the effects on hair cells over the short term in vitro may not be the same as ototoxicity produced in vivo where the damage develops over longer periods and where much lower concentrations can be ototoxic (Pickles, 2008) . Long-term consequences of ototoxic drug use, especially at lower doses than commonly believed to cause ototoxicity, have not been adequately studied, and more research studies still need to be conducted in this field. Future studies with large diverse elderly populations are needed to replicate the findings of this study, thus expanding the generalizability of the findings.
Implications
Our findings support that known ototoxic medications are widely used for treating various conditions, and ototoxicity may interact with aging, leading to a more severe hearing loss than that associated with only age. Given the high prevalence of hearing loss and its impact on health and activities of daily living, the high prevalence of ototoxic medication use by older adults may be a critical public health problem. Their use highlights the potential for increased hearing loss as a result of the increased use of ototoxic medications to treat chronic illnesses loss across time. Nurse practitioners (NPs) may not consider ototoxic side effects or consider them less important than the main effect of the drug when they choose medications for certain diseases (Albert et al., 2011 
